These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 6303588)

  • 1. Mitoxantrone for treatment of patients with refractory small cell carcinoma of the lung: a Southwest Oncology Group Study.
    Von Hoff DD; Chen T; Clark GM; Callahan SK; Livingston R
    Cancer Treat Rep; 1983 Apr; 67(4):403-4. PubMed ID: 6303588
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.
    Taylor SA; Von Hoff DD; Baker LH; Balcerzak SP
    Cancer Treat Rep; 1984 Jun; 68(6):919-20. PubMed ID: 6733708
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II evaluation of mitoxantrone in patients with bronchogenic carcinoma: a Southeastern Cancer Study Group trial.
    Kramer BS; Gams R; Birch R; Einhorn L; Buchanan R
    Cancer Treat Rep; 1984 Oct; 68(10):1295-6. PubMed ID: 6525601
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II trial of mitoxantrone in previously untreated patients with colorectal adenocarcinoma: A Southwest Oncology Group Study.
    Cowan JD; Von Hoff DD; McDonald B; Talley RW; McCracken JD; Chen T
    Cancer Treat Rep; 1982 Sep; 66(9):1779-80. PubMed ID: 7116355
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study.
    Bull FE; Von Hoff DD; Balcerzak SP; Stephens RL; Panettiere FJ
    Cancer Treat Rep; 1985 Feb; 69(2):231-3. PubMed ID: 3882233
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II evaluation of mitoxantrone in advanced renal cell carcinoma: a Southeastern Cancer Study Group Trial.
    Gams RA; Nelson O; Birch R
    Cancer Treat Rep; 1986 Jul; 70(7):921-2. PubMed ID: 3521848
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II evaluation of mitoxantrone in advanced carcinoma of the stomach: a Southeastern Cancer Study Group Trial.
    DeSimone PA; Gams R; Birch R
    Cancer Treat Rep; 1986 Aug; 70(8):1043-4. PubMed ID: 3524836
    [No Abstract]   [Full Text] [Related]  

  • 8. Mitoxantrone and advanced squamous cell carcinoma of the cervix: a Southwest Oncology Group Study.
    Hilgers RD; Von Hoff DD; Stephens RL; Boutselis JG
    Cancer Treat Rep; 1986 Apr; 70(4):527-8. PubMed ID: 3698047
    [No Abstract]   [Full Text] [Related]  

  • 9. Mitoxantrone in malignant melanoma.
    Presant CA; Gams R; Bartolucci A
    Cancer Treat Rep; 1984 Jun; 68(6):903-5. PubMed ID: 6733704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of mitoxantrone in refractory germ cell tumors: a trial of the Southeastern Cancer Study Group.
    Williams SD; Birch R; Gams R; Irwin L
    Cancer Treat Rep; 1985 Dec; 69(12):1455-6. PubMed ID: 3000593
    [No Abstract]   [Full Text] [Related]  

  • 11. Weekly mitoxantrone in the treatment of advanced pancreatic carcinoma: a Southeastern Cancer Study Group Trial.
    DeSimone PA; Gams R; Bartolucci A
    Cancer Treat Rep; 1986 Jul; 70(7):929-30. PubMed ID: 3521850
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II trial of AMSA in patients with refractory small cell carcinoma of the lung.
    Fuks JZ; Van Echo DA; Aisner J; Von Hoff D; Wiernik PH
    Cancer Treat Rep; 1981; 65(1-2):133-4. PubMed ID: 6261947
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II trial of mitoxantrone in advanced colorectal cancer.
    Bonnem EM; Mitchell EP; Woolley PV; Smith FP; Neefe J; Smith L; Schein PS
    Cancer Treat Rep; 1982 Nov; 66(11):1995-6. PubMed ID: 7139642
    [No Abstract]   [Full Text] [Related]  

  • 14. [Phase II study of mitoxantrone].
    Tada A; Ogawa M; Usui N; Inagaki J; Horikoshi N; Inoue K; Ikeda K; Adachi K; Nakada H; Okada Y
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1649-54. PubMed ID: 6476838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of mitoxantrone, aclarubicin, and diaziquone in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study.
    Ettinger DS; Finkelstein DM; Harper GR; Ruckdeschel JC; Chang AY; Camacho FJ; Marsh JC; Silber R; Wolter JM
    Cancer Treat Rep; 1985 Sep; 69(9):1033-4. PubMed ID: 3861248
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II evaluation of triazinate in patients with metastatic lung cancer.
    Creagan ET; Eagan RT; Fleming TR; Frytak S; Ingle JN; Kvols LK; Nichols WC
    Cancer Treat Rep; 1980; 64(10-11):1057-9. PubMed ID: 6257389
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study.
    Alberts DS; Balcerzak SP; Bonnet JD; Stephens RL
    Cancer Treat Rep; 1985 Nov; 69(11):1321-3. PubMed ID: 4092195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II clinical evaluation of dihydroxyanthracenedione in patients with advanced lung cancer.
    Valdivieso M; Umsawasdi T; Spitzer G; Chiuten DF; Booser DJ; Dhingra HM; Bodey GP
    Am J Clin Oncol; 1984 Jun; 7(3):241-4. PubMed ID: 6328968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of mitoxantrone in patients with primary liver cancer.
    Falkson G; Coetzer BJ; Terblanche AP
    Cancer Treat Rep; 1984 Oct; 68(10):1311-2. PubMed ID: 6525607
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II trial of mitoxantrone.
    Anderson KC; Cohen GI; Garnick MB
    Cancer Treat Rep; 1982 Nov; 66(11):1929-31. PubMed ID: 7139638
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.